First time at CPhi Russia for Presspart
Presspart, the leading supplier of respiratory drug delivery components, will be exhibiting for the first time at CPhi Russia, Moscow on stand 234 from the 30th March- 1st April 2016
CPhI Russia is a content-led exhibition and networking event which hosts a range of exhibitors in the field of pharma ingredients, finished dosage, machinery, equipment, technology and outsourcing, this event is a unique opportunity to initiate business and build partnerships in the booming Russian and CIS pharma markets.
As the market leader in the manufacture of respiratory drug delivery components, including metered-dose inhaler canisters and actuators, it was only naturally that Presspart has taken the opportunity to showcase its product and service capabilities to the pharmaceutical market in what is one of the fastest growing markets.
As well as their full range of metered-dose inhaler components, Presspart will also be showcasing on their wide range of healthcare dispensing actuators which are available for a variety of applications including oral, topical and aural.
For the first time at a CPhi event, Presspart will be exhibiting their latest innovation, the Quantum Dose Indicator for MDI’s. The patented Quantum end of life indicator has been developed to be a low cost, disposable dose indicator solution, ensuring patients don’t run out of their medication when they need it the most.
Visitors can also learn more about Presspart’s Inhalation Product Technology Centre (IPTC)The IPTC was introduced to further expand Presspart’s R&D capabilities in the respiratory drug delivery market. As the world’s leading manufacturer of metered-dose inhaler components, it was only fitting that Presspart should introduce this industry first. The IPTC will deliver the capabilities to support new product developments and strategic initiatives with our customers.
CPhi Russia runs from the 30-1 April 2016 in Moscow and Presspart are located on stand 234. For more information or to arrange a meeting at the show with the Presspart team please contact us.